Parenteral clomipramine compared to other treatment in obsessive compulsive disorder (OCD)

Reading time approx. 1 minute
This page contains 1 evidence gap
  1. Parenteral clomipramine compared to other treatment in obsessive compulsive disorder (OCD)
Population:
Patients with obsessive compulsive disorder (OCD)
Intervention:
Clomipramine via parenteral administration
Comparison:
Other treatment (e.g. electroconvulsive therapy or other medication(s))
Outcomes:
OCD symptoms, suicide attempt, all-cause mortality, suicidal ideation, global functioning, treatment discontinuation, length of hospital stay, health-related quality of life (HROL), adverse events related to administration via injection/infusion

What evidence is needed?

More primary research is needed.

What evidence is available?

Reliable systematic reviews that show evidence gaps:

Ioannou M, Falk Ö, Gustavsson J, Khan J, Nilsson J, Sjögren P, Steingrimsson S, Svanberg T, Szabó Z, Wallerstedt SM. Efficacy and safety of parenteral clomipramine compared to oral clomipramine or other treatments for depression or obsessive-compulsive disorder [Effekt och säkerhet för parenteral klomipraminbehandling vid depression respektive tvångssyndrom]. Göteborg: Västra Götalandsregionen, Sahlgrenska Universitetssjukhuset, HTA-centrum; 2025. Regional activity based HTA 2025:144. More about the review

Reliable, but not updated, systematic reviews that show evidence gaps:

None identified

Registration number:
Published:
Research conducted after publication could potentially change the nature of the evidence.
To top

Evidence gap identifies methods or practices for which no conclusive systematic review of benefits and harms has been published. Gaps in scientific evidence appear on the SBU website to help researchers and granting agencies identify areas that are in need of research or systematic review. An additional objective is to offer healthcare and social service providers a basis for setting priorities.